首页 > 最新文献

International Journal of Breast Cancer最新文献

英文 中文
Labels, Language, and Other Strategies to Improve Communication About Lower Grade Forms of Ductal Carcinoma In Situ of the Breast: A National Delphi Survey.
IF 1.6 Q4 ONCOLOGY Pub Date : 2025-02-17 eCollection Date: 2025-01-01 DOI: 10.1155/ijbc/8642832
Mavis S Lyons, Genevieve Chaput, Antonio Finelli, Rachel Kupets, Nicole Look Hong, Frances C Wright, Anna R Gagliardi

Purpose: This study is aimed at generating consensus among women who had ductal carcinoma in situ (DCIS) and healthcare professionals on how to improve communication about low-risk forms of DCIS and reduce affected women's diagnosis-related confusion and anxiety. Methods: We conducted a two-round online Delphi survey with affected women and professionals from across Canada. They rated items sourced from prior research and key informant interviews on a 7-point Likert scale. We retained items rated 6 or 7 by ≥ 80% of panelists. Results: Thirty-seven panelists (17 women, 20 professionals) completed Round 1 and 94.6% of those completed Round 2. Of 42 items rated, 18 were retained, 13 discarded, and 11 did not achieve consensus to retain or discard. Women and professionals agreed on 3 language approaches (use plain language, distinguish DCIS from invasive breast cancer, specify the risk of recurrence and spread) and 9 other strategies to help discuss DCIS (e.g., use visual aids, provide or refer women to culturally tailored DCIS-specific information, ensure physicians can access interpreters). Based on rating and comments, women were more enthusiastic than professionals about referring to abnormal cells rather than DCIS and scheduling longer or follow-up visits to address concerns. To disseminate these findings, panelists recommended public awareness campaigns for women and continuing education and professional society endorsement for physicians. Conclusion: These findings address gaps in prior research that recommended changing the DCIS label, but had not fully explored label preferences, or identified other ways to improve and support communication about DCIS.

{"title":"Labels, Language, and Other Strategies to Improve Communication About Lower Grade Forms of Ductal Carcinoma In Situ of the Breast: A National Delphi Survey.","authors":"Mavis S Lyons, Genevieve Chaput, Antonio Finelli, Rachel Kupets, Nicole Look Hong, Frances C Wright, Anna R Gagliardi","doi":"10.1155/ijbc/8642832","DOIUrl":"10.1155/ijbc/8642832","url":null,"abstract":"<p><p><b>Purpose:</b> This study is aimed at generating consensus among women who had ductal carcinoma in situ (DCIS) and healthcare professionals on how to improve communication about low-risk forms of DCIS and reduce affected women's diagnosis-related confusion and anxiety. <b>Methods:</b> We conducted a two-round online Delphi survey with affected women and professionals from across Canada. They rated items sourced from prior research and key informant interviews on a 7-point Likert scale. We retained items rated 6 or 7 by ≥ 80% of panelists. <b>Results:</b> Thirty-seven panelists (17 women, 20 professionals) completed Round 1 and 94.6% of those completed Round 2. Of 42 items rated, 18 were retained, 13 discarded, and 11 did not achieve consensus to retain or discard. Women and professionals agreed on 3 language approaches (use plain language, distinguish DCIS from invasive breast cancer, specify the risk of recurrence and spread) and 9 other strategies to help discuss DCIS (e.g., use visual aids, provide or refer women to culturally tailored DCIS-specific information, ensure physicians can access interpreters). Based on rating and comments, women were more enthusiastic than professionals about referring to abnormal cells rather than DCIS and scheduling longer or follow-up visits to address concerns. To disseminate these findings, panelists recommended public awareness campaigns for women and continuing education and professional society endorsement for physicians. <b>Conclusion:</b> These findings address gaps in prior research that recommended changing the DCIS label, but had not fully explored label preferences, or identified other ways to improve and support communication about DCIS.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2025 ","pages":"8642832"},"PeriodicalIF":1.6,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11850068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143494034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhancing Skin Cancer Diagnosis Through Fine-Tuning of Pretrained Models: A Two-Phase Transfer Learning Approach.
IF 1.6 Q4 ONCOLOGY Pub Date : 2025-02-17 eCollection Date: 2025-01-01 DOI: 10.1155/ijbc/4362941
Entesar Hamed I Eliwa

Skin cancer is among the most prevalent types of cancer worldwide, and early detection is crucial for improving treatment outcomes and patient survival rates. Traditional diagnostic methods, often reliant on visual examination and manual evaluation, can be subjective and time-consuming, leading to variability in accuracy. Recent developments in machine learning, particularly using pretrained models and fine-tuning techniques, offer promising advancements in automating and improving skin cancer classification. This paper explores the application of a two-phase model using the HAM10000 dataset, which comprises a wide range of skin lesion images. The first phase employs transfer learning with frozen layers, followed by fine-tuning all layers in the second phase to adapt the models more specifically to the dataset. I evaluate nine pretrained models, including VGG16, VGG19, InceptionV3, Xception (extreme inception), and DenseNet121, assessing their performance based on accuracy, precision, recall, and F1 score metrics. The VGG16 model, after fine-tuning, achieved the highest test set accuracy of 99.3%, highlighting its potential for highly accurate skin cancer classification. This study provides important insights for clinicians and researchers, demonstrating the efficacy of advanced machine learning models in enhancing diagnostic accuracy and supporting clinical decision-making in dermatology.

{"title":"Enhancing Skin Cancer Diagnosis Through Fine-Tuning of Pretrained Models: A Two-Phase Transfer Learning Approach.","authors":"Entesar Hamed I Eliwa","doi":"10.1155/ijbc/4362941","DOIUrl":"10.1155/ijbc/4362941","url":null,"abstract":"<p><p>Skin cancer is among the most prevalent types of cancer worldwide, and early detection is crucial for improving treatment outcomes and patient survival rates. Traditional diagnostic methods, often reliant on visual examination and manual evaluation, can be subjective and time-consuming, leading to variability in accuracy. Recent developments in machine learning, particularly using pretrained models and fine-tuning techniques, offer promising advancements in automating and improving skin cancer classification. This paper explores the application of a two-phase model using the HAM10000 dataset, which comprises a wide range of skin lesion images. The first phase employs transfer learning with frozen layers, followed by fine-tuning all layers in the second phase to adapt the models more specifically to the dataset. I evaluate nine pretrained models, including VGG16, VGG19, InceptionV3, Xception (extreme inception), and DenseNet121, assessing their performance based on accuracy, precision, recall, and <i>F</i>1 score metrics. The VGG16 model, after fine-tuning, achieved the highest test set accuracy of 99.3%, highlighting its potential for highly accurate skin cancer classification. This study provides important insights for clinicians and researchers, demonstrating the efficacy of advanced machine learning models in enhancing diagnostic accuracy and supporting clinical decision-making in dermatology.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2025 ","pages":"4362941"},"PeriodicalIF":1.6,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11850074/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143494031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reactive Axillary Lymphadenopathy Among Different COVID-19 Vaccines: A Retrospective Study in Breast Sonography.
IF 1.6 Q4 ONCOLOGY Pub Date : 2025-02-15 eCollection Date: 2025-01-01 DOI: 10.1155/ijbc/8126974
Pin-Chi Huang, Chia-Hui Chen, Chiao-Hsuan Chien, Chen-Hui Chen, Chin-Yu Chen

Background/Purpose: During the coronavirus disease 2019 (COVID-19) outbreak, reactive lymphadenopathy after vaccination is a major concern in breast sonography, especially for patients with a history of breast cancer. The state-of-the-art literature on clinical and sonographic findings either examines a small volume of cases or limited types of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. This study is aimed at providing vast clinical information to facilitate breast sonographic examination for participants who underwent recent SARS-CoV-2 vaccination. Methods: Among different SARS-CoV-2 vaccines in the Asian Taiwanese population, reactive axillary lymphadenopathy was investigated through breast sonographic findings and clinical data analysis. The sample included participants with recent vaccination by different brands approved in Taiwan, such as the AstraZeneca ChAdOx1 (AZ) vaccine, Moderna mRNA-1273 (Moderna) vaccine, and Pfizer-BioNTech BNT162b2 (BNT) vaccine. Results: A total of 291 participants received the AZ vaccine, 154 received the BNT vaccine, 222 received the Moderna vaccine, and 422 were nonvaccinated during the study period. The incidence rate for axillary reactive lymphadenopathy was 10.9, 21.3, 21.4, and 0.6, respectively. No incidence of malignancy was reported during the 6-month follow-up period. The AZ vaccine, which is a virus-vector vaccine reported a lower incidence rate than mRNA vaccines. We also found lymphadenopathy may last for more than 1 month after vaccination in this study. Conclusion: The study results provide additional supporting information for the management suggested by the recently updated revision of the Society of Breast Imaging guideline pertaining to lymphadenopathy diagnosis of SARS-CoV-2 vaccine-related ipsilateral lymphadenopathy and screening of mammograms.

{"title":"Reactive Axillary Lymphadenopathy Among Different COVID-19 Vaccines: A Retrospective Study in Breast Sonography.","authors":"Pin-Chi Huang, Chia-Hui Chen, Chiao-Hsuan Chien, Chen-Hui Chen, Chin-Yu Chen","doi":"10.1155/ijbc/8126974","DOIUrl":"10.1155/ijbc/8126974","url":null,"abstract":"<p><p><b>Background/Purpose:</b> During the coronavirus disease 2019 (COVID-19) outbreak, reactive lymphadenopathy after vaccination is a major concern in breast sonography, especially for patients with a history of breast cancer. The state-of-the-art literature on clinical and sonographic findings either examines a small volume of cases or limited types of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. This study is aimed at providing vast clinical information to facilitate breast sonographic examination for participants who underwent recent SARS-CoV-2 vaccination. <b>Methods:</b> Among different SARS-CoV-2 vaccines in the Asian Taiwanese population, reactive axillary lymphadenopathy was investigated through breast sonographic findings and clinical data analysis. The sample included participants with recent vaccination by different brands approved in Taiwan, such as the AstraZeneca ChAdOx1 (AZ) vaccine, Moderna mRNA-1273 (Moderna) vaccine, and Pfizer-BioNTech BNT162b2 (BNT) vaccine. <b>Results:</b> A total of 291 participants received the AZ vaccine, 154 received the BNT vaccine, 222 received the Moderna vaccine, and 422 were nonvaccinated during the study period. The incidence rate for axillary reactive lymphadenopathy was 10.9, 21.3, 21.4, and 0.6, respectively. No incidence of malignancy was reported during the 6-month follow-up period. The AZ vaccine, which is a virus-vector vaccine reported a lower incidence rate than mRNA vaccines. We also found lymphadenopathy may last for more than 1 month after vaccination in this study. <b>Conclusion:</b> The study results provide additional supporting information for the management suggested by the recently updated revision of the Society of Breast Imaging guideline pertaining to lymphadenopathy diagnosis of SARS-CoV-2 vaccine-related ipsilateral lymphadenopathy and screening of mammograms.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2025 ","pages":"8126974"},"PeriodicalIF":1.6,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11846679/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143484222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hydroxytyrosol, a Component of Olive Oil for Breast Cancer Prevention in Women at High Risk of Cancer.
IF 1.6 Q4 ONCOLOGY Pub Date : 2025-01-21 eCollection Date: 2025-01-01 DOI: 10.1155/ijbc/8831168
Akshjot Puri, Zheng Yin, Sergio Granados-Principal, Joe Ensor, Liliana Guzman, Roberto Rosato, Hong Zhao, Stephen Wong, Lin Wang, Tejal Patel, Jenny C Chang

Background: This study evaluates the effects of hydroxytyrosol (HT), a component of olive oil, on mammographic breast density reduction. We explored effects of HT on Wnt β-catenin and other pathways involved in cancer stem cell renewal, DNA repair, cell proliferation, and differentiation. Methods: Twenty-five milligrams per day oral dose of HT was given for 12 months in pre- and postmenopausal women at increased risk of breast cancer. Out of 51 patients enrolled, 41 completed the study. The annualized percent decrease in maximum mammographic volumetric breast density (max VBD%) between baseline (BL) and end of treatment (EOT) was analyzed. RNA sequencing (RNA-Seq) and multiplex analysis was performed on the breast biopsies to compare the BL with EOT samples. Results: Max VBD% showed a nonsignificant change; however, in women 60 years or older, the max VBD% decrease was significant (3.7%, p = 0.0391), especially in those with high BL mammographic density. Using RNA-Seq, 3330 unique transcripts were identified (p < 0.05). Mitotic telophase/cytokinesis and DNA damage were upregulated, whereas Wnt, Notch, and oxidative stress-induced senescence pathways were downregulated (p < 0.05). These pathways were confirmed by NanoString nCounter where significant decrease in proliferative genes (RELA and CDK4) and Wnt pathway (R-HSA-195721 and R-HAS-201681) was observed (p < 0.05). Conclusions: HT reduced breast density only in women over 60 years, especially in those with high BL breast density. HT also reduced proliferation and affected the Wnt signaling pathway. This study lays the foundation for future larger studies in exploring a natural compound with well tolerability and overall nontoxic profile for chemoprevention of breast cancer. Trial Registration: ClinicalTrials.gov identifier: NCT02068092.

{"title":"Hydroxytyrosol, a Component of Olive Oil for Breast Cancer Prevention in Women at High Risk of Cancer.","authors":"Akshjot Puri, Zheng Yin, Sergio Granados-Principal, Joe Ensor, Liliana Guzman, Roberto Rosato, Hong Zhao, Stephen Wong, Lin Wang, Tejal Patel, Jenny C Chang","doi":"10.1155/ijbc/8831168","DOIUrl":"10.1155/ijbc/8831168","url":null,"abstract":"<p><p><b>Background:</b> This study evaluates the effects of hydroxytyrosol (HT), a component of olive oil, on mammographic breast density reduction. We explored effects of HT on Wnt <i>β</i>-catenin and other pathways involved in cancer stem cell renewal, DNA repair, cell proliferation, and differentiation. <b>Methods:</b> Twenty-five milligrams per day oral dose of HT was given for 12 months in pre- and postmenopausal women at increased risk of breast cancer. Out of 51 patients enrolled, 41 completed the study. The annualized percent decrease in maximum mammographic volumetric breast density (max VBD%) between baseline (BL) and end of treatment (EOT) was analyzed. RNA sequencing (RNA-Seq) and multiplex analysis was performed on the breast biopsies to compare the BL with EOT samples. <b>Results:</b> Max VBD% showed a nonsignificant change; however, in women 60 years or older, the max VBD% decrease was significant (3.7%, <i>p</i> = 0.0391), especially in those with high BL mammographic density. Using RNA-Seq, 3330 unique transcripts were identified (<i>p</i> < 0.05). Mitotic telophase/cytokinesis and DNA damage were upregulated, whereas Wnt, Notch, and oxidative stress-induced senescence pathways were downregulated (<i>p</i> < 0.05). These pathways were confirmed by NanoString nCounter where significant decrease in proliferative genes (RELA and CDK4) and Wnt pathway (R-HSA-195721 and R-HAS-201681) was observed (<i>p</i> < 0.05). <b>Conclusions:</b> HT reduced breast density only in women over 60 years, especially in those with high BL breast density. HT also reduced proliferation and affected the Wnt signaling pathway. This study lays the foundation for future larger studies in exploring a natural compound with well tolerability and overall nontoxic profile for chemoprevention of breast cancer. <b>Trial Registration:</b> ClinicalTrials.gov identifier: NCT02068092.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2025 ","pages":"8831168"},"PeriodicalIF":1.6,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11774573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143068699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness of TachoSil as Sealant in Lymphatic Leakage of Breast Cancer With Axillary Dissection. TachoSil作为封闭剂治疗乳腺癌伴腋窝清扫淋巴渗漏的疗效。
IF 1.6 Q4 ONCOLOGY Pub Date : 2024-12-31 eCollection Date: 2024-01-01 DOI: 10.1155/ijbc/3765406
ArshadUllah Khan, Loai Albinsaad, Mohammed Alessa, Alghaydaa Fouad Aldoughan, Ammar Jaafar Alsalem, Noof Khalid Almukhaimar, Abdulrahman Ahmed Alghamdi, Watan Abdulla Alsahlawi, Batool Abdullah Alahmary

Objectives: This study is aimed at evaluating the effectiveness of TachoSil in controlling lymphatic leakage in breast cancer patients undergoing axillary dissection. By examining its ability to reduce postsurgical lymphatic drainage, the study will assess its impact on complications like seroma formation, recovery time, and overall patient outcomes, including quality of life and reduced healthcare costs. Methods: Breast cancer patients treated in the Department of Surgical Oncology at King Abdulaziz Medical City were enrolled to receive either TachoSil or undergo drain placement after axillary dissection. Repeated measures multivariate analysis of variance (MANOVA) was used to observe the difference in lymphatic drainage volume over time considering other covariates, such as age, sex, family history, neoadjuvant chemotherapy (NAC), and stage. Results: The TachoSil group showed significantly lower lymphatic drainage volumes at 24 h (106.5 ± 11.3) than the control group (141.7 ± 13.0) (p < 0.001). There were no significant differences in lymphatic drainage volume at 3 days (p = 0.176) and 7 days (p = 0.091). However, at 10 days, the TachoSil group exhibited significantly lower lymphatic drainage volume (19.9 ± 6.1) than the control group (44.5 ± 9.2) (p < 0.001). Repeated measures MANOVA showed a statistically significant difference in lymphatic drainage over time, with a moderate effect (p < 0.001). Conclusion: The findings suggest that TachoSil sealant effectively reduces early postoperative lymphatic drainage volume and maintains lower drainage rates up to 10 days following axillary dissection in breast cancer patients. The use of TachoSil sealant may have potential benefits in reducing the incidence of complications associated with lymphatic drainage and improving patient outcomes.

目的:评价TachoSil对乳腺癌腋窝清扫患者淋巴渗漏的控制效果。通过检查其减少术后淋巴引流的能力,该研究将评估其对血肿形成、恢复时间和患者整体预后(包括生活质量和降低医疗成本)等并发症的影响。方法:在阿卜杜勒阿齐兹国王医疗城外科肿瘤科接受治疗的乳腺癌患者在腋窝清扫后接受TachoSil或引流。考虑其他协变量,如年龄、性别、家族史、新辅助化疗(NAC)和分期,采用重复测量多变量方差分析(MANOVA)观察淋巴引流量随时间的差异。结果:TachoSil组24 h淋巴引流量(106.5±11.3)明显低于对照组(141.7±13.0)(p < 0.001)。3 d淋巴引流量(p = 0.176)和7 d淋巴引流量(p = 0.091)差异无统计学意义。然而,在第10天,TachoSil组淋巴引流量(19.9±6.1)明显低于对照组(44.5±9.2)(p < 0.001)。重复测量方差分析显示,淋巴引流随时间的变化有统计学意义,影响中等(p < 0.001)。结论:TachoSil密封剂可有效减少乳腺癌患者术后早期淋巴引流量,并在腋窝清扫后10天内保持较低的引流率。使用TachoSil密封剂可能在减少与淋巴引流相关的并发症发生率和改善患者预后方面具有潜在的益处。
{"title":"Effectiveness of TachoSil as Sealant in Lymphatic Leakage of Breast Cancer With Axillary Dissection.","authors":"ArshadUllah Khan, Loai Albinsaad, Mohammed Alessa, Alghaydaa Fouad Aldoughan, Ammar Jaafar Alsalem, Noof Khalid Almukhaimar, Abdulrahman Ahmed Alghamdi, Watan Abdulla Alsahlawi, Batool Abdullah Alahmary","doi":"10.1155/ijbc/3765406","DOIUrl":"https://doi.org/10.1155/ijbc/3765406","url":null,"abstract":"<p><p><b>Objectives:</b> This study is aimed at evaluating the effectiveness of TachoSil in controlling lymphatic leakage in breast cancer patients undergoing axillary dissection. By examining its ability to reduce postsurgical lymphatic drainage, the study will assess its impact on complications like seroma formation, recovery time, and overall patient outcomes, including quality of life and reduced healthcare costs. <b>Methods:</b> Breast cancer patients treated in the Department of Surgical Oncology at King Abdulaziz Medical City were enrolled to receive either TachoSil or undergo drain placement after axillary dissection. Repeated measures multivariate analysis of variance (MANOVA) was used to observe the difference in lymphatic drainage volume over time considering other covariates, such as age, sex, family history, neoadjuvant chemotherapy (NAC), and stage. <b>Results:</b> The TachoSil group showed significantly lower lymphatic drainage volumes at 24 h (106.5 ± 11.3) than the control group (141.7 ± 13.0) (<i>p</i> < 0.001). There were no significant differences in lymphatic drainage volume at 3 days (<i>p</i> = 0.176) and 7 days (<i>p</i> = 0.091). However, at 10 days, the TachoSil group exhibited significantly lower lymphatic drainage volume (19.9 ± 6.1) than the control group (44.5 ± 9.2) (<i>p</i> < 0.001). Repeated measures MANOVA showed a statistically significant difference in lymphatic drainage over time, with a moderate effect (<i>p</i> < 0.001). <b>Conclusion:</b> The findings suggest that TachoSil sealant effectively reduces early postoperative lymphatic drainage volume and maintains lower drainage rates up to 10 days following axillary dissection in breast cancer patients. The use of TachoSil sealant may have potential benefits in reducing the incidence of complications associated with lymphatic drainage and improving patient outcomes.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2024 ","pages":"3765406"},"PeriodicalIF":1.6,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11707064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142956233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness of a Breast Cancer Educational Conference Targeting Healthcare Workers in Honduras. 针对洪都拉斯医护人员的乳腺癌教育会议的效果。
IF 1.6 Q4 ONCOLOGY Pub Date : 2024-12-21 eCollection Date: 2024-01-01 DOI: 10.1155/ijbc/1855494
Saranya Prathibha, Mario Zuniga, Suyapa Bejarano, Flora Duarte, Merlin Antunez, Alejandra Z Molina, Noelle Hoven, Schelomo Marmor, Jennifer Witt, Jane Hui, Todd M Tuttle

Purpose: Previous studies have demonstrated that many healthcare workers in low- and middle-income countries (LMICs) lack the appropriate training and knowledge to recognize and diagnose breast cancer at an early stage. As a result, women in LMICs are frequently diagnosed with late-stage breast cancer (Stage III/IV) with a poor prognosis. Materials and Methods: We hosted a 1-day breast cancer educational conference directed towards healthcare workers in Honduras. We conducted pre- and postcourse (1-2 months later) assessments that evaluated knowledge of screening, diagnosis, and treatment of breast cancer. Breast cancer specialists at the University of Minnesota and Honduras developed a 12-question assessment tool in Spanish. Results: A total of 157 people attended the course, and 86 completed the precourse knowledge assessment. The overall percentage of correct responses was 70% in the precourse assessment. Postcourse knowledge assessments were completed by 94 participants. The overall percentage of correct responses was 80% in the postcourse assessment and was significantly higher than precourse assessment scores (p < 0.0001). For the individual domains of screening, diagnosis, and treatment, the postcourse knowledge assessment scores were significantly improved as compared with the precourse scores (p < 0.0001). Conclusion: In this study, we found that a 1-day, in-person breast cancer educational course directed towards healthcare workers in Honduras resulted in improved breast cancer knowledge assessment scores. Future research and implementation strategies will include training healthcare workers throughout Honduras and determining the impact of these educational interventions on the late-stage presentation of breast cancer.

目的:以前的研究表明,低收入和中等收入国家(LMICs)的许多卫生保健工作者缺乏适当的培训和知识,无法在早期阶段识别和诊断乳腺癌。因此,低收入和中等收入国家的妇女经常被诊断为晚期乳腺癌(III/IV期),预后较差。材料和方法:我们在洪都拉斯举办了为期1天的针对卫生保健工作者的乳腺癌教育会议。我们进行了术前和术后(1-2个月后)评估,评估了乳腺癌的筛查、诊断和治疗知识。明尼苏达大学和洪都拉斯的乳腺癌专家用西班牙语开发了一个有12个问题的评估工具。结果:157人参加课程,86人完成课前知识评估。在课前评估中,正确回答的总体百分比为70%。94名参与者完成了课后知识评估。课程后评估的总体正确率为80%,显著高于课程前评估得分(p < 0.0001)。对于筛查、诊断和治疗的各个领域,课程后知识评估得分与课程前得分相比显着提高(p < 0.0001)。结论:在本研究中,我们发现针对洪都拉斯医护人员的为期1天的面对面乳腺癌教育课程提高了乳腺癌知识评估分数。未来的研究和实施战略将包括培训洪都拉斯各地的卫生保健工作者,并确定这些教育干预措施对乳腺癌晚期表现的影响。
{"title":"Effectiveness of a Breast Cancer Educational Conference Targeting Healthcare Workers in Honduras.","authors":"Saranya Prathibha, Mario Zuniga, Suyapa Bejarano, Flora Duarte, Merlin Antunez, Alejandra Z Molina, Noelle Hoven, Schelomo Marmor, Jennifer Witt, Jane Hui, Todd M Tuttle","doi":"10.1155/ijbc/1855494","DOIUrl":"10.1155/ijbc/1855494","url":null,"abstract":"<p><p><b>Purpose:</b> Previous studies have demonstrated that many healthcare workers in low- and middle-income countries (LMICs) lack the appropriate training and knowledge to recognize and diagnose breast cancer at an early stage. As a result, women in LMICs are frequently diagnosed with late-stage breast cancer (Stage III/IV) with a poor prognosis. <b>Materials and Methods:</b> We hosted a 1-day breast cancer educational conference directed towards healthcare workers in Honduras. We conducted pre- and postcourse (1-2 months later) assessments that evaluated knowledge of screening, diagnosis, and treatment of breast cancer. Breast cancer specialists at the University of Minnesota and Honduras developed a 12-question assessment tool in Spanish. <b>Results:</b> A total of 157 people attended the course, and 86 completed the precourse knowledge assessment. The overall percentage of correct responses was 70% in the precourse assessment. Postcourse knowledge assessments were completed by 94 participants. The overall percentage of correct responses was 80% in the postcourse assessment and was significantly higher than precourse assessment scores (<i>p</i> < 0.0001). For the individual domains of screening, diagnosis, and treatment, the postcourse knowledge assessment scores were significantly improved as compared with the precourse scores (<i>p</i> < 0.0001). <b>Conclusion:</b> In this study, we found that a 1-day, in-person breast cancer educational course directed towards healthcare workers in Honduras resulted in improved breast cancer knowledge assessment scores. Future research and implementation strategies will include training healthcare workers throughout Honduras and determining the impact of these educational interventions on the late-stage presentation of breast cancer.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2024 ","pages":"1855494"},"PeriodicalIF":1.6,"publicationDate":"2024-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681979/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenges and Innovations in Breast Cancer Screening in India: A Review of Epidemiological Trends and Diagnostic Strategies. 印度乳腺癌筛查的挑战和创新:流行病学趋势和诊断策略综述。
IF 1.6 Q4 ONCOLOGY Pub Date : 2024-11-28 eCollection Date: 2024-01-01 DOI: 10.1155/ijbc/6845966
Induni Nayodhara Weerarathna, Anurag Luharia, Ashish Uke, Gaurav Mishra

The intricate terrain of breast cancer (BC) in India is examined in this review, which also looks at screening techniques, geographical differences, epidemiological trends, and obstacles to early diagnosis. BC has a major impact in India, especially on women. The research examines data from 2014 to 2024 and finds that, although overall cancer rates are declining, there has been a noticeable increase in BC cases. While obstacles including late-stage diagnosis and restricted access to treatment contribute to lower survival rates in India compared to Western countries, regional variations underscore the need for customized screening measures. The analysis of screening methods highlights the particular difficulties that Indian women encounter, such as the limitations of mammography in a country whose breast density is higher. The review presents cutting-edge technologies like breast exams and computer-aided detection and examines alternative techniques like ultrasonography. The importance of healthcare spending on screening uptake is highlighted by the regional inequality discussion, and mobile screening camps have emerged as a workable way to get around access and cost issues. The relevance of patient education and awareness in the Indian context is emphasized in the review's conclusion. The lack of adequate health resources and sociocultural obstacles, such as the fear of cancer, highlight the necessity of early detection campaigns and thorough education programs. With a knowledge of the difficulties and achievements in BC screening procedures, this narrative review hopes to make a significant contribution to the larger conversation about managing BC in the particular setting of India.

本文审查了印度乳腺癌(BC)的复杂地形,还研究了筛查技术、地理差异、流行病学趋势和早期诊断的障碍。英国广播公司在印度有很大的影响,尤其是对女性。该研究检查了2014年至2024年的数据,发现尽管总体癌症发病率在下降,但BC病例却明显增加。虽然与西方国家相比,包括晚期诊断和获得治疗的限制在内的障碍导致印度的生存率较低,但区域差异强调了定制筛查措施的必要性。对筛查方法的分析突出了印度妇女遇到的特殊困难,例如在一个乳房密度较高的国家,乳房x光检查的局限性。这篇综述介绍了乳房检查和计算机辅助检测等尖端技术,并研究了超声检查等替代技术。区域不平等讨论强调了医疗保健支出对筛查吸收的重要性,移动筛查营地已经成为解决获取和成本问题的可行方法。在审查的结论中强调了在印度背景下患者教育和意识的相关性。缺乏足够的卫生资源和社会文化障碍,例如对癌症的恐惧,突出了早期发现运动和全面教育方案的必要性。了解BC筛查程序的困难和成就后,本文的叙述性综述希望对在印度特定环境下管理BC的更大对话做出重大贡献。
{"title":"Challenges and Innovations in Breast Cancer Screening in India: A Review of Epidemiological Trends and Diagnostic Strategies.","authors":"Induni Nayodhara Weerarathna, Anurag Luharia, Ashish Uke, Gaurav Mishra","doi":"10.1155/ijbc/6845966","DOIUrl":"10.1155/ijbc/6845966","url":null,"abstract":"<p><p>The intricate terrain of breast cancer (BC) in India is examined in this review, which also looks at screening techniques, geographical differences, epidemiological trends, and obstacles to early diagnosis. BC has a major impact in India, especially on women. The research examines data from 2014 to 2024 and finds that, although overall cancer rates are declining, there has been a noticeable increase in BC cases. While obstacles including late-stage diagnosis and restricted access to treatment contribute to lower survival rates in India compared to Western countries, regional variations underscore the need for customized screening measures. The analysis of screening methods highlights the particular difficulties that Indian women encounter, such as the limitations of mammography in a country whose breast density is higher. The review presents cutting-edge technologies like breast exams and computer-aided detection and examines alternative techniques like ultrasonography. The importance of healthcare spending on screening uptake is highlighted by the regional inequality discussion, and mobile screening camps have emerged as a workable way to get around access and cost issues. The relevance of patient education and awareness in the Indian context is emphasized in the review's conclusion. The lack of adequate health resources and sociocultural obstacles, such as the fear of cancer, highlight the necessity of early detection campaigns and thorough education programs. With a knowledge of the difficulties and achievements in BC screening procedures, this narrative review hopes to make a significant contribution to the larger conversation about managing BC in the particular setting of India.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2024 ","pages":"6845966"},"PeriodicalIF":1.6,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11620809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142787256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neoadjuvant Chemotherapy Shortens the cfDNA Telomere Length in Breast Cancer Patients. 新辅助化疗会缩短乳腺癌患者的 cfDNA 端粒长度
IF 1.6 Q4 ONCOLOGY Pub Date : 2024-11-14 eCollection Date: 2024-01-01 DOI: 10.1155/2024/6117394
İrem Peker Eyüboğlu, Sinan Koca, Betül Çelik, Gökçe Güllü Amuran, M Ümit Uğurlu, Özkan Alan, Tuğba Akın Telli, Perran Fulden Yumuk, Mustafa Akkiprik

Introduction: Cancer is a genetic disease that affects people worldwide, and breast cancer is the most common cancer in women. Studies have been conducted on molecular parameters to predict tumor behavior and develop therapeutic strategies. Telomeres, which are at the end of chromosomes, have been studied for their relationship with breast cancer, but more research is needed to understand their role in the disease. Circulating-free DNA (cfDNA) is DNA that is free in the bloodstream and is considered a promising target for early cancer detection, treatment response monitoring, and prognosis assessment. This study is aimed at comparing cfDNA telomere length of breast cancer patients and healthy individuals and analyzing the impact of neoadjuvant chemotherapy on telomere length in cfDNA. Materials and Methods: Blood samples were collected from 33 breast cancer patients undergoing neoadjuvant chemotherapy before and after treatment. The quantitative PCR method is used to measure the average telomere lengths. Results: This study found that the telomere length of cfDNA in breast cancer patients before and after treatment is significantly shorter than in the control group. Neoadjuvant chemotherapy is found to shorten the cfDNA telomere length, especially in the treatment-responsive group. Conclusion: Our study suggests that telomere length in cfDNA may be a useful biomarker for predicting therapy response and possible reoccurrence of the disease in breast cancer patients.

导言癌症是一种遗传性疾病,影响着全世界的人们,而乳腺癌是女性最常见的癌症。人们对分子参数进行了研究,以预测肿瘤行为并制定治疗策略。位于染色体末端的端粒与乳腺癌的关系已得到研究,但还需要更多的研究来了解端粒在乳腺癌中的作用。循环游离DNA(cfDNA)是游离在血液中的DNA,被认为是早期癌症检测、治疗反应监测和预后评估的理想靶点。本研究旨在比较乳腺癌患者和健康人的 cfDNA 端粒长度,并分析新辅助化疗对 cfDNA 端粒长度的影响。材料和方法:采集33名接受新辅助化疗的乳腺癌患者治疗前后的血液样本。采用定量 PCR 方法测量端粒的平均长度。结果:本研究发现,乳腺癌患者在治疗前后的 cfDNA 端粒长度明显短于对照组。发现新辅助化疗会缩短cfDNA端粒长度,尤其是在治疗反应组。结论我们的研究表明,cfDNA 中的端粒长度可能是预测乳腺癌患者治疗反应和可能复发的有用生物标志物。
{"title":"Neoadjuvant Chemotherapy Shortens the cfDNA Telomere Length in Breast Cancer Patients.","authors":"İrem Peker Eyüboğlu, Sinan Koca, Betül Çelik, Gökçe Güllü Amuran, M Ümit Uğurlu, Özkan Alan, Tuğba Akın Telli, Perran Fulden Yumuk, Mustafa Akkiprik","doi":"10.1155/2024/6117394","DOIUrl":"10.1155/2024/6117394","url":null,"abstract":"<p><p><b>Introduction:</b> Cancer is a genetic disease that affects people worldwide, and breast cancer is the most common cancer in women. Studies have been conducted on molecular parameters to predict tumor behavior and develop therapeutic strategies. Telomeres, which are at the end of chromosomes, have been studied for their relationship with breast cancer, but more research is needed to understand their role in the disease. Circulating-free DNA (cfDNA) is DNA that is free in the bloodstream and is considered a promising target for early cancer detection, treatment response monitoring, and prognosis assessment. This study is aimed at comparing cfDNA telomere length of breast cancer patients and healthy individuals and analyzing the impact of neoadjuvant chemotherapy on telomere length in cfDNA. <b>Materials and Methods:</b> Blood samples were collected from 33 breast cancer patients undergoing neoadjuvant chemotherapy before and after treatment. The quantitative PCR method is used to measure the average telomere lengths. <b>Results:</b> This study found that the telomere length of cfDNA in breast cancer patients before and after treatment is significantly shorter than in the control group. Neoadjuvant chemotherapy is found to shorten the cfDNA telomere length, especially in the treatment-responsive group. <b>Conclusion:</b> Our study suggests that telomere length in cfDNA may be a useful biomarker for predicting therapy response and possible reoccurrence of the disease in breast cancer patients.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2024 ","pages":"6117394"},"PeriodicalIF":1.6,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581796/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes From Real-World Data on Intraoperative Electronic Radiotherapy for the Treatment of Early-Stage Breast Cancer: Long-Term Recurrence and Survival Outcomes From a Single Center. 术中电子放疗治疗早期乳腺癌的真实世界数据结果:来自单一中心的长期复发和生存结果。
IF 1.6 Q4 ONCOLOGY Pub Date : 2024-11-14 eCollection Date: 2024-01-01 DOI: 10.1155/2024/6207762
Dolores De la Mata, Bernardino Gabriel Santiago-Concha, Juan Enrique Bargalló-Rocha, Carlos Daniel Robles-Vidal, Daniella Gómez-Pue, Gerardo Castorena-Rojí, José Hinojosa-Gómez, Fabiola Flores-Vázquez, Mónika Blake-Cerda, Mario Enriquez-Barrera, Antonio Maffuz-Aziz

Purpose: This study is aimed at investigating the 10-year outcomes of intraoperative radiotherapy (IORT) in Mexican women with early breast cancer (EBC) treated at the Centro Medico ABC, Mexico City. Methods: A cohort study included women with early-stage invasive ductal carcinoma aged ≥ 45 years without prior oncologic treatment, tumor size ≤ 3.5 cm, cN0M0, positive hormone receptors, margins ≥ 2 mm, negative sentinel lymph nodes, and no extensive lymphovascular invasion. IORT was administered at 20 Gy for 20-30 min after a lumpectomy. Follow-up extended over 10 years and included clinical examinations every 6 months for the first 18 months, followed by annual mammograms and conventional examinations. Patients out of the criteria were excluded from this study because they were referred for additional surgery and/or whole-breast radiation therapy. Results: The study involved 238 patients with an average age of 61.1 years. The mean tumor size was 12 mm, and the percentages of lymphatic invasion, positive hormone receptors, and HER2/neu overexpression were 12.6%, 90.8%, and 2.1%, respectively. The median follow-up was 66.6 months (range: 1-126 months), and the overall survival and mastectomy-free rate reached 95.7% and 90%, respectively. Thirteen patients showed side effects; four recurrences were recorded, of which 50% were out-field relapses. The 5-year Kaplan-Meier probability of local relapses, mastectomy-free, and overall survival reached 97.5%, 100%, and 98%, respectively. Conclusions: This is the first 10-year report about the effect of IORT on Mexican women with EBC in the early stages. Strict adherence to the selection criteria in this study resulted in low rates of side effects, mortality, and local recurrences, demonstrating that IORT is an effective treatment alternative for patients with EBC. Studies with a longer follow-up period should be performed, as recurrences can occur in the long term.

目的:本研究旨在调查在墨西哥城 ABC 医学中心接受早期乳腺癌 (EBC) 治疗的墨西哥妇女术中放疗 (IORT) 的 10 年疗效。研究方法:一项队列研究纳入了年龄≥45岁、未接受过肿瘤治疗、肿瘤大小≤3.5厘米、cN0M0、激素受体阳性、边缘≥2毫米、前哨淋巴结阴性、无广泛淋巴管侵犯的早期浸润性导管癌女性患者。IORT在肿块切除术后进行,每次20 Gy,20-30分钟。随访时间长达10年,包括前18个月每6个月进行一次临床检查,之后每年进行一次乳房X光检查和常规检查。本研究排除了不符合标准的患者,因为他们被转诊接受了额外的手术和/或全乳放射治疗。研究结果研究共涉及 238 名患者,平均年龄为 61.1 岁。肿瘤平均大小为 12 毫米,淋巴侵犯、激素受体阳性和 HER2/neu 过表达的比例分别为 12.6%、90.8% 和 2.1%。中位随访时间为 66.6 个月(范围:1-126 个月),总生存率和无乳腺切除率分别达到 95.7% 和 90%。13名患者出现了副作用;4例复发,其中50%为外地复发。局部复发、无乳房切除和总生存的5年Kaplan-Meier概率分别达到97.5%、100%和98%。结论:这是第一份关于 IORT 对早期 EBC 墨西哥女性患者影响的 10 年报告。该研究严格遵守选择标准,副作用、死亡率和局部复发率都很低,这表明 IORT 是治疗 EBC 患者的有效替代方法。由于长期治疗可能会出现复发,因此应进行更长时间的随访研究。
{"title":"Outcomes From Real-World Data on Intraoperative Electronic Radiotherapy for the Treatment of Early-Stage Breast Cancer: Long-Term Recurrence and Survival Outcomes From a Single Center.","authors":"Dolores De la Mata, Bernardino Gabriel Santiago-Concha, Juan Enrique Bargalló-Rocha, Carlos Daniel Robles-Vidal, Daniella Gómez-Pue, Gerardo Castorena-Rojí, José Hinojosa-Gómez, Fabiola Flores-Vázquez, Mónika Blake-Cerda, Mario Enriquez-Barrera, Antonio Maffuz-Aziz","doi":"10.1155/2024/6207762","DOIUrl":"10.1155/2024/6207762","url":null,"abstract":"<p><p><b>Purpose:</b> This study is aimed at investigating the 10-year outcomes of intraoperative radiotherapy (IORT) in Mexican women with early breast cancer (EBC) treated at the Centro Medico ABC, Mexico City. <b>Methods:</b> A cohort study included women with early-stage invasive ductal carcinoma aged ≥ 45 years without prior oncologic treatment, tumor size ≤ 3.5 cm, cN0M0, positive hormone receptors, margins ≥ 2 mm, negative sentinel lymph nodes, and no extensive lymphovascular invasion. IORT was administered at 20 Gy for 20-30 min after a lumpectomy. Follow-up extended over 10 years and included clinical examinations every 6 months for the first 18 months, followed by annual mammograms and conventional examinations. Patients out of the criteria were excluded from this study because they were referred for additional surgery and/or whole-breast radiation therapy. <b>Results:</b> The study involved 238 patients with an average age of 61.1 years. The mean tumor size was 12 mm, and the percentages of lymphatic invasion, positive hormone receptors, and HER2/neu overexpression were 12.6%, 90.8%, and 2.1%, respectively. The median follow-up was 66.6 months (range: 1-126 months), and the overall survival and mastectomy-free rate reached 95.7% and 90%, respectively. Thirteen patients showed side effects; four recurrences were recorded, of which 50% were out-field relapses. The 5-year Kaplan-Meier probability of local relapses, mastectomy-free, and overall survival reached 97.5%, 100%, and 98%, respectively. <b>Conclusions:</b> This is the first 10-year report about the effect of IORT on Mexican women with EBC in the early stages. Strict adherence to the selection criteria in this study resulted in low rates of side effects, mortality, and local recurrences, demonstrating that IORT is an effective treatment alternative for patients with EBC. Studies with a longer follow-up period should be performed, as recurrences can occur in the long term.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2024 ","pages":"6207762"},"PeriodicalIF":1.6,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581795/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142689213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of a Culturally Appropriate Text Messaging Platform for Improving Breast Cancer Screening Uptake Among Ghanaian Women in Metropolitan Areas. 开发与文化相适应的短信平台,提高大都市地区加纳妇女的乳腺癌筛查率。
IF 1.6 Q4 ONCOLOGY Pub Date : 2024-10-24 eCollection Date: 2024-01-01 DOI: 10.1155/2024/5587515
Ransford Paul Selasi Sefenu, Adolphina Addoley Addo-Lartey, Harriet Affran Bonful, Adanna Nwameme, Timothy Agandah Abagre, Adolf Kofi Awua, Kofi Agyabeng, Kwabena Oteng Birimpong, Nii Armah Adu-Aryee, Florence Dedey, Richard Mawuena Kofi Adanu, Kolawole Stephen Okuyemi

Objective: Early detection through screening could improve breast cancer (BC) outcomes in sub-Saharan Africa (SSA). We explored women's preferences for BC-related mobile health text messaging, described the development of a mobile-health text messaging platform, and examined the enablers and barriers to BC screening. Methods: A concurrent mixed-method study of women aged 40-59 years was conducted. Four essential actions were carried out: (i) a baseline survey of 130 women, (ii) five focus group discussions (FGDs), (iii) a stakeholder meeting with BC research and clinical treatment specialists, and (iv) text message pretesting. The survey and FGD findings were used to create a culturally appropriate SMS platform for BC screening. Results: Thirty-five text messages were developed and evaluated with the following communication goals in mind: 15 addressed BC awareness, six emphasized the importance of early detection, five alleviated anxieties as a barrier to BC screening, seven encouraged women to prioritize their health, and three indicated screening locations and costs. The majority (92.6%) of survey respondents who had heard of mammography (54/130) said screening was necessary. Fear of the screening procedure, receiving a positive diagnosis, and other testing-related worries (40.7%) were identified as potential barriers to BC screening, along with low income (18.5%), a lack of BC-related indicators (9.3%), insufficient breast awareness education (9.3%), and time restrictions (7.4%). The presence of BC-related symptoms (27.8%), breast awareness education (24.1%), and doctor's advice (16.7%) were all potential facilitators of BC screening uptake. The majority of FGD participants favored brief texts, with 42.3% preferring one text message per day. Conclusion: Several factors limit women from accessing BC screening services; nevertheless, specific barriers such as a lack of BC education, time constraints, and disease fears can be successfully targeted through SMS messaging interventions to encourage women to use BC screening programs.

目的:通过筛查及早发现可改善撒哈拉以南非洲地区(SSA)的乳腺癌(BC)治疗效果。我们探讨了妇女对与乳腺癌相关的移动健康短信的偏好,介绍了移动健康短信平台的开发情况,并研究了乳腺癌筛查的促进因素和障碍。研究方法对 40-59 岁的女性进行了一项同步混合方法研究。开展了四项基本行动:(i) 对 130 名妇女进行基线调查,(ii) 进行五次焦点小组讨论 (FGD),(iii) 与 BC 研究和临床治疗专家举行利益相关者会议,以及 (iv) 进行短信预试。调查和 FGD 的结果被用于创建一个适合不同文化背景的 BC 筛查短信平台。结果开发并评估了 35 条短信,其传播目标如下:其中 15 条涉及对 BC 的认识,6 条强调了早期发现的重要性,5 条缓解了作为 BC 筛查障碍的焦虑,7 条鼓励妇女优先考虑自己的健康,3 条指出了筛查地点和费用。大多数(92.6%)听说过乳房 X 线照相术的受访者(54/130)认为筛查是必要的。对筛查过程的恐惧、得到阳性诊断以及其他与检查相关的担忧(40.7%)被认为是乳腺增生筛查的潜在障碍,此外还有低收入(18.5%)、缺乏乳腺增生相关指标(9.3%)、乳腺知识教育不足(9.3%)以及时间限制(7.4%)。出现乳腺癌相关症状(27.8%)、乳腺知识教育(24.1%)和医生建议(16.7%)都是接受乳腺癌筛查的潜在促进因素。大多数 FGD 参与者喜欢简短的短信,42.3% 的人喜欢每天一条短信。结论有几个因素限制了妇女接受子宫颈癌筛查服务;然而,一些特定的障碍,如缺乏子宫颈癌教育、时间限制和对疾病的恐惧等,都可以通过短信干预成功地解决,以鼓励妇女使用子宫颈癌筛查项目。
{"title":"Development of a Culturally Appropriate Text Messaging Platform for Improving Breast Cancer Screening Uptake Among Ghanaian Women in Metropolitan Areas.","authors":"Ransford Paul Selasi Sefenu, Adolphina Addoley Addo-Lartey, Harriet Affran Bonful, Adanna Nwameme, Timothy Agandah Abagre, Adolf Kofi Awua, Kofi Agyabeng, Kwabena Oteng Birimpong, Nii Armah Adu-Aryee, Florence Dedey, Richard Mawuena Kofi Adanu, Kolawole Stephen Okuyemi","doi":"10.1155/2024/5587515","DOIUrl":"10.1155/2024/5587515","url":null,"abstract":"<p><p><b>Objective:</b> Early detection through screening could improve breast cancer (BC) outcomes in sub-Saharan Africa (SSA). We explored women's preferences for BC-related mobile health text messaging, described the development of a mobile-health text messaging platform, and examined the enablers and barriers to BC screening. <b>Methods:</b> A concurrent mixed-method study of women aged 40-59 years was conducted. Four essential actions were carried out: (i) a baseline survey of 130 women, (ii) five focus group discussions (FGDs), (iii) a stakeholder meeting with BC research and clinical treatment specialists, and (iv) text message pretesting. The survey and FGD findings were used to create a culturally appropriate SMS platform for BC screening. <b>Results:</b> Thirty-five text messages were developed and evaluated with the following communication goals in mind: 15 addressed BC awareness, six emphasized the importance of early detection, five alleviated anxieties as a barrier to BC screening, seven encouraged women to prioritize their health, and three indicated screening locations and costs. The majority (92.6%) of survey respondents who had heard of mammography (54/130) said screening was necessary. Fear of the screening procedure, receiving a positive diagnosis, and other testing-related worries (40.7%) were identified as potential barriers to BC screening, along with low income (18.5%), a lack of BC-related indicators (9.3%), insufficient breast awareness education (9.3%), and time restrictions (7.4%). The presence of BC-related symptoms (27.8%), breast awareness education (24.1%), and doctor's advice (16.7%) were all potential facilitators of BC screening uptake. The majority of FGD participants favored brief texts, with 42.3% preferring one text message per day. <b>Conclusion:</b> Several factors limit women from accessing BC screening services; nevertheless, specific barriers such as a lack of BC education, time constraints, and disease fears can be successfully targeted through SMS messaging interventions to encourage women to use BC screening programs.</p>","PeriodicalId":46159,"journal":{"name":"International Journal of Breast Cancer","volume":"2024 ","pages":"5587515"},"PeriodicalIF":1.6,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11527544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142559112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Breast Cancer
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1